Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol

Last updated: August 25, 2023
Sponsor: University Hospital, Toulouse
Overall Status: Active - Recruiting

Phase

3

Condition

Post-traumatic Stress Disorders

Treatment

Placebo

Propranolol Oral Product

memory reactivation

Clinical Study ID

NCT04985344
RC31/18/0471
2020-005956-39
  • Ages 7-12
  • All Genders

Study Summary

By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out.

The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory.

Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children aged 7-12 years
  • CPTS-RI total score ≥40
  • Primary diagnosis of PTSD (6 months or more after the traumatic event)
  • Heart rate ≥ 55 bpm
  • Systolic blood pressure ≥ 95 mm Hg
  • Affiliation to a social security scheme
  • Written consent signed by the parents/holders of parental authority and theinvestigator
  • Acceptance of the protocol by the child-Child and Parents/Holders of parentalauthority fluent in French

Exclusion

Exclusion Criteria:

  • Age<7 years or ≥13 years
  • Children whose parents have been deprived of their authority
  • Contraindication to propranolol (cardiogenic shock, sinus bradycardia, hypotension (<fifth percentile oscillometric or <2SD) (Banker et al., 2016 - see APPENDIX 1),greater than first-degree heart block, heart failure, bronchial asthma andhypersensitivity to propranolol hydrochloride)
  • Concurrent medication with possible interactions with propranolol (cf 8.2)
  • Concurrent psychotropic drugs that have been shown to be effective in improvingsymptoms of PTSD (Antidepressants, atypical antipsychotics, mood stabilizers)
  • Concurrent psychotherapy (>1 structured session/month declared by the clinician whofollows the child)
  • Current active psychosis, anorexia nervosa, bulimia nervosa, binge-eating disorder,attention-deficit hyperactivity disorder, autism spectrum disorder
  • Children with psoriasis
  • Children with a predisposition to hypoglycemia
  • Obsessive-compulsive disorders
  • Bipolar Disorders
  • Mental retardation,
  • Traumatic brain injury (loss of consciousness > 10 minutes)
  • Currently treated with a bradycardic drug
  • Concurrent participation to another interventional study
  • Renal or Hepatic Impairment
  • Pregnancy

Study Design

Total Participants: 92
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 3
Study Start date:
February 01, 2023
Estimated Completion Date:
September 30, 2027

Study Description

By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out.

The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory.

Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.

The combination of the targeted reactivation of the traumatic memory and the intake of an agent that decreases the reconsolidation can thus disrupt the recall of unwanted memories and thus serve as a treatment for people suffering from traumatic memories, such as in PTSD.

Since stimulation of β-noradrenergic receptors facilitates the consolidation of memories as well as their re-consolidation, an antagonist of these receptors, propranolol, has generated considerable interest as a treatment to alleviate emotional and traumatic memories in individuals with PTSD.

In adults diagnosed with long-standing PTSD two 6-week, double-blind, placebocontrolled, randomised clinical trials, one in 60 subjects and the other in 67 have shown promising results. PTSD participants who actively recalled their traumatic event under the influence of propranolol once a week for up to 6 weeks showed a substantial decrease in symptom ratings compared with placebo. Thus, all of this data led the team to propose a comparable design study in children with PTSD

Connect with a study center

  • Toulouse University Hospital

    Toulouse, 31059
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.